Prepubertal obese children who took metformin had lower body mass index z-scores as well as better inflammatory and cardiovascular-related obesity parameters after six months, compared with those who received placebo, Spanish researchers reported in Pediatrics. However, the findings, based on data involving 160 Spanish youths ages 7 to 14, didn't show benefits in pubertal youths who received the drug.
Prepubertal obese youths may benefit from metformin
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.